Mathias Oelke

Mathias Oelke

Auto-generated profile, based on publicly available information

Mathias Oelke

Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MOMathias Oelke
Mathias Oelke
MMMarcela V. Maus
Marcela V. Maus
DDDominic Didiano
Dominic Didiano
CJCarl H. June
Carl H. June
AMAndreas Mackensen
Andreas Mackensen
JSJonathan P. Schneck
Jonathan P. Schneck

1 August 2009
Verified
Journal Article
Closed access
RGRobert L Giuntoli
Robert L Giuntoli
TWTonya Webb
Tonya Webb
AZAlessia Zoso
Alessia Zoso
OROphelia Rogers
Ophelia Rogers
TDTeresa P Diaz-Montes
Teresa P Diaz-Montes
MOMathias Oelke
Mathias Oelke

31 July 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
TWTonya Webb
Tonya Webb
XLXiangming Li
Xiangming Li
RGRobert L. Giuntoli
Robert L. Giuntoli
PLPablo H.H. Lopez
Pablo H.H. Lopez
CHChristoph Heuser
Christoph Heuser
JSJonathan P. Schneck
Jonathan P. Schneck
Tumors often display mechanisms to avoid or suppress immune recognition. One such mechanism is the shedding of gangliosides into the local tumor microenvironment, and a high concentration of circulating gangliosides is associated with poor prognosis. In this study, we identify ganglioside GD3, which was isolated from the polar lipid fraction of ovarian cancer–associated ascites, as an inhibitory factor that prevents innate immune activation of natural killer T (NKT) cells. Purified GD3 displayed a high affinity for both human and mouse CD1d, a molecule involved in the presentation of lipid antigens to T cells. Purified GD3, as well as substances within the ascites, bound to the CD1d antigenic-binding site and did not require additional processing for its inhibitory effect on NKT cells. Importantly, in vivo administration of GD3 inhibited α-galactosylceramide (α-GalCer)-induced NKT cell activation in a dose-dependent manner. These data therefore indicate that ovarian cancer tumors may use GD3 to inhibit the antitumor NKT cell response as an early mechanism of tumor immune evasion. Cancer Res; 72(15); 3744–52. ©2012 AACR.

14 December 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
SUStefano Ugel
Stefano Ugel
AZAlessia Zoso
Alessia Zoso
CSCarmela De Santo
Carmela De Santo
YLYu Li
Yu Li
IMIlaria Marigo
Ilaria Marigo
VBVincenzo Bronte
Vincenzo Bronte
The development of effective antitumor immune responses is normally constrained by low-avidity, tumor-specific CTLs that are unable to eradicate the tumor. Strategies to rescue antitumor activity of low-avidity melanoma-specific CTLs in vivo may improve immunotherapy efficacy. To boost the in vivo effectiveness of low-avidity CTLs, we immunized mice bearing lung melanoma metastases with artificial antigen-presenting cells (aAPC), made by covalently coupling pepMHC-Ig dimers and B7.1-Ig molecules to magnetic beads. aAPC treatment induced significant tumor reduction in a mouse telomerase antigen system, and complete tumor eradication in a mouse TRP-2 antigen system, when low-avidity CTLs specific for these antigens were adoptively transferred. In addition, in an in vivo treatment model of subcutaneous melanoma, aAPC injection also augmented the activity of adoptively transferred CTLs and significantly delayed tumor growth. In vivo tumor clearance due to aAPC administration correlated with in situ proliferation of the transferred CTL. In vitro studies showed that aAPC effectively stimulated cytokine release, enhanced CTL-mediated lysis, and TCR downregulation in low-avidity CTLs. Therefore, in vivo aAPC administration represents a potentially novel approach to improve cancer immunotherapy. [Cancer Res 2009;69(24):9376–84]

25 January 2001 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TKToshiro Kurokawa
Toshiro Kurokawa
MOMathias Oelke
Mathias Oelke
AMAndreas Mackensen
Andreas Mackensen
Melanoma and renal cell carcinoma (RCC) are considered to be the most immunogenic tumors in humans. To generate conditions to induce primary T‐cell responses against RCC and to allow further expansion of tumor‐specific cytotoxic T lymphocytes (CTL) for adoptive transfer, peripheral blood mononuclear cells from RCC patients were stimulated with primary autologous tumor cells or monocyte‐derived dendritic cells (DC) loaded with either tumor lysate (TU‐LY) or apoptotic tumor cells (TU‐AP). Whereas repetitive stimulation (4×) with tumor cells alone induced a predominant population of CD3− natural killer cells, 4 weeks of stimulation with tumor‐loaded DC favored induction and expansion of CD4+ T cells (>80%). However, 2 weekly stimulation cycles with tumor‐loaded DC followed by restimulation with autologous irradiated tumor cells alone were optimal for induction of tumor‐specific CTL responses in vitro. Using these culture conditions a marked increase of CD4+ T cells was observed during the first 2 weeks of stimulation with tumor‐loaded DC. Subsequent restimulation with autologous tumor cells alone gave rise to 500‐fold expansion of CD8+ T cells. These CD8+ T cells were shown to exhibit strong major histocompatibility complex class I‐restricted cytotoxic activity against the autologous tumor. Comparison of TU‐LY and TU‐AP as a source of tumor antigen for loading DC did not show any difference in stimulating tumor‐specific CTL. Length pattern analysis of the complementary determining region 3 (CDR3) of the T‐cell receptor Vβ chain revealed expansion of oligoclonal CTL populations with outgrowth of 1 or 2 clones after prolonged stimulation with autologous tumor cells. Our study demonstrated an efficient method for generating tumor‐specific CTL in vitro that may be used to identify tumor cell antigens or that can be expanded for adoptive T‐cell transfer in tumor immunotherapy.

1 July 2010 in Journal of Lipid Research
Verified
Journal Article
Open access
JHJing Hua
Jing Hua
XMXiong Ma
Xiong Ma
TWTonya Webb
Tonya Webb
JPJames J. Potter
James J. Potter
MOMathias Oelke
Mathias Oelke
ZLZhiping Li
Zhiping Li
Dietary fatty acids are major contributors to the development and progression of insulin resistance and nonalcoholic fatty liver disease (NAFLD). Dietary fatty acids also alter hepatic NKT cells that are activated by antigens presented by CD1d. In the current study, we examine the mechanism of dietary fatty acid induced hepatic NKT cell deficiency and its causal relationship to insulin resistance and NAFLD. We discover that dietary saturated fatty acids (SFA) or monounsaturated fatty acids (MUFA), but not polyunsaturated fatty acids (PUFA), cause hepatic NKT cell depletion with increased apoptosis. Dietary SFA or MUFA also impair hepatocyte presentation of endogenous, but not exogenous, antigen to NKT cells, indicating alterations of the endogenous antigen processing or presenting pathway. In vitro treatment of normal hepatocytes with fatty acids also demonstrates impaired ability of CD1d to present endogenous antigen by dietary fatty acids. Furthermore, dietary SFA and MUFA activate the NFkappaB signaling pathway and lead to insulin resistance and hepatic steatosis. In conclusion, both dietary SFA and MUFA alter endogenous antigen presentation to hepatic NKT cells and contribute to NKT cell depletion, leading to further activation of inflammatory signaling, insulin resistance, and hepatic steatosis.